Comité de Honor 

Comité Científico  

Comité Técnico 

Registrarse

Programa  

Comunicaciones

Instrucciones para el IRC (chat)

BIBLIOGRAFÍA

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-250 (Medline)
2.  Wilentz JR, Sandborn TA, Haudenschild CC, et al. Platelet accumulation in experimental angioplasty: time course and relation to cardiovascular injury. Circulation. 1987;75:636-642 (Medline)
3.  Coller BS. Platelets and thrombolytic therapy. N Engl J Med. 1990;322:33-42 (Medline)
4.  Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med. 1999;341:319-327 (Texto completo)
5.  Cho L, Topol EJ, Balog C, et al. Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. J Am Coll Cardiol. 2000;36:381-386 (Medline)
6.  Sabatine, MS, Jang, IK. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Am J Med 2000; 109:224-237 (Medline)
7.  Simoons ML, and the GUSTO IV-ACS investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001; 357: 1915-1924 (Medline) (Texto completo)
8. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised,placebo-controlled trial. Lancet 2000; 356:2037-44 (Medline) (Texto completo)
9. The EPISTENT Investigators.Randomised placebo-controlled and balloon-angi plasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.Lancet 1998;352:87-92 (Medline) (Texto completo)
10. Kong DF,Califf RM,Miller DP,et al.Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.Circulation 1998;98:2829-35 (Medline) (Texto completo)
11. Boersma E,  Akkerhuis KM,  Théroux P, Califf RM, Topol EJ, Simoons ML.Platelet Glycoprotein IIb/IIIa Receptor Inhibition in Non-ST-Elevation Acute Coronary Syndromes Early Benefit During Medical Treatment Only, With Additional Protection During Percutaneous Coronary Intervention. Circulation. 1999;100:2045-2048 (Medline) (Texto completo)
12. Bhatt DL, Marso SP, Lincoff AM, et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol. 2000;35:922-928 (Medline)
13. Narins CR, Miller DP, Califf RM, Topol EJ. The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization. J Am Coll Cardiol. 1999;33:647-653 (Medline)
14. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961 (Medline) (Texto completo)
15. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696 (Medline) (Texto completo)
16. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 1997;349:1429-1435 (Medline)
17. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87-92 (Medline) (Texto completo)
18.  Topol EJ. Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and Back-up Abciximab] Events Trial (CACHET). Am J Cardiol. 1998;82:63P-68P (Medline)
19.  Topol EJ,Moliterno DJ,Herrmann HC,et al.Comparison of two platelet glyc pr tein IIb/IIIa inhibitors,tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.N Engl J Med 2001;344:1888-94 . (Medline)
20.  The PURSUIT Trial Investigators.Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43 (Medline) (Texto completo)
21.  The PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338:1498-1505 (Medline) (Texto completo)
22.  The PRISM-PLUS Study Investigators.Inhibition of the platelet glycopr oein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave my cardial infarction.N Engl J Med 1998;338:1488-97.[Erratum, N Engl J Med 1998;339:415.] (Medline) (Medline) (Texto completo)
23.  The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation. 1998;97:2386-2395 (Medline) (Texto completo)
24.  Moliterno DJ for the PARAGON B International Steering Committee: Patient Specific Dosing of IIb-IIIa antagonists during acute coronary syndromes: Rationale and desing of the PARAGON B study. Am H Journal 2000;  139:563-566 (Medline) (Texto completo)
25.  Chew DP. A Critical appraisal of platelet glycoprotein IIb-IIIa inhibition. J Am Coll Cardiol 2000.36:2028-2035 (Medline)
26.  Latour Pérez J. Risks and benefits of glycoprotein IIb-IIIa antagonists in acute coronary syndromes. Ann Pharmacother 2001;35:472-479 (Medline)
27.  Newby LK, Christenson RH, Ohman M, et al for the GUSTO-IIa investigators. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. Circulation 1998;98:1853-1859 (Medline) (Texto completo)
28.  Ohman EM, Armstrong PW, White HD, et al for the GUSTO-III Investigators. Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. Am J Cardiol. 1999;84:1281-1286 (Medline)
29.  Benamer H, Steg PG, Benessiano J, et al. Comparison of the prognostic value of C-reactive protein and troponin I in patients with unstable angina pectoris. Am J Cardiol. 1998;82:845-850 (Medline)
30.  Newby LK, Ohman EM, Christenson RH, Moliterno DJ, Harrington RA, White HD, Armstrong PW, Van De Werf F, Pfisterer M, Hasselblad V, Califf RM, Topol EJ: Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: the PARAGON-B troponin T substudy. Circulation 2001; 103: 2891-2896 (Medline) (Texto completo)
31.  Heeschen C, Hamm CW, Bruemmer J, Simoons ML, for the CAPTURE Investigators. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. J Am Coll Cardiol. 2000;35:1535-1542 (Medline)
32.  Versaci F, Gaspardone A, Tomai F, Crea F, Chiarello L, Gioffré PA. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. Am J Cardiol. 2000;85:92-95 (Medline)
33.  B den WE,O 'Rourke RA,Crawford MH,et al.Outcomes in patients with acute non -Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med 1998;338:1785-92.[Erratum,N Engl J Med 1998;339:1091.] (Medline) (Texto completo)
34.  Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non -Q-wave myocardial infarction: results of the TIMI IIIB Trial.Circulation 1994;89: 1545-56 (Medline)
35.  Cannon CP,Weintraub WS,Demopoulos LA,et al.Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87 (Medline) (Texto completo)
36.  Antman EM,Cohen M,Bernink P ,et al.The TIMI risk score for unstable angina/non-ST elevation MI:a method for prognostication and therapeutic decision making.AMA 2000;284:835-42 (Medline)
37.   Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354:708-15 (Medline) (Texto completo)
38.  The IMPACT-II Investigators.Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary interven tion:IMPACT-II.Lancet 1997;349:1422-8 (Medline)
39.  Zhao XQ, Théroux P, Snapinn SM, Sax FL, for the PRISM-PLUS Investigators. Intracoronary Thrombus and Platelet Glycoprotein IIb/IIIa Receptor Blockade With Tirofiban in Unstable Angina or Non-Q-Wave Myocardial Infarction. Circulation. 1999;100:1609-1615 (Medline) (Texto completo)
40.  McAlister FA.  JAMA 1999; 128 (14): 1371377
41.  Braunwald E. The open-artery is alive and well-again. N Eng J Med 1993;329:1650-1652 (Medline)
42.  Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI)-14 trial. The TIMI-14 Investigators. Circulation. 1999;99:2720-2732 (Medline) (Texto completo)
43.  de Lemos JA, Antman EM, Gibson CM, et al. abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: observations from the TIMI-14 trial. Circulation. 2000;101:239-243 (Medline) (Texto completo)
44.  Neumann FJ, Ott I, Gawaz M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation. 1995;92:748-755 (Medline) (Texto completo)
45.  Gawaz M, Neumann FJ, Dickfeld T, et al. Vitronectin receptor (alpha (v) beta 3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction. Circulation. 1997;96:1809-1818 (Medline) (Texto completo)
46.  Furman MI, Krueger LA, Frelinger AL, et al. Tirofiban and eptifibatide, but not abciximab, induce leukocyte-platelet aggregation. Circulation. 1999;100:I-681
47.  Herrmann HC,Molitern DJ,Ohman EM,et al.Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute my cardial infarction:results from the SPEED (GUSTO-4 Pilot)Trial.J Am Coll Cardiol 2000;36:1489-96. (Medline)
48.  Brodie BR, Stuckey TD, Hansen C, Muncy D. Benefits of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. Am J Cardiol. 2000;85:13-18 (Medline)
49.  The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357: 1905-14 (Medline) (Texto completo)
50.  Nunn CM, O'Neill WW, Rothbaum D, et al. Long-term outcome after primary angioplasty in myocardial infarction (PAMI-I) trial. J Am Coll Cardiol. 1999;33:640-646 (Medline)
51.  Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1997;336:1621-1628. (Medline) (Texto completo)
52.  Weaver WD, Cerquerla M, Hallstron AP, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy: the Myocardial Infarction Triage and Intervention Trial. JAMA. 1993;270:1211-1216. (Medline)
53.  Simoons ML, Betriu A, Col J, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet. 1988;1:197-203. (Medline)
54.  SWIFT (Should We Intervene Following Thrombolysis?) Trial Study Group. SWIFT trial of delayed elective intervention v conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. Br Med J. 1991;302:555-560. (Medline)
55.  Ross AM, Coyne KS, Reiner JS, et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT Investigators: Plasminogen-Activator Angioplasty compatibility Trial. J Am Coll Cardiol.  1999;34:1954-1962 (Medline)
56.  Stone GW,Grines CL,Cox DA,et al.A prospective,randomized trial comparing primary balloon angi plasty with or without abciximab t primary stenting with or without abciximab in acute my cardial infarction: primary endpoint analysis from the CADILLAC Trial.Circulation 2000; 102:II-664.abstract
57.  Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction: ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation. 1998;98:734-741 (Medline) (Texto completo)
58.  Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation. 1998;98:2695-2701 (Medline) (Texto completo)
59.  Montalescot G,Barragan P,Wittenberg O,et al.Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute my cardial infarction. N Engl J Med 2001;344:1895-903 (Medline) (Texto completo)
60.  ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction: Executive Summary and Recommendation. Circulation 2000;102:1193-1209. (Medline) (Texto completo)
61.  Management of acute coronary syndromes: acute coronary syndromes wifhout persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology. European Heart Journal (2000) 21, 1406-1432 (Medline) (Texto completo)
62.  López-Bescós L, Fernández-Ortiz A, Bueno Zamor H, Coma Canella I, Lidón RM, Cequier A, et al . Guías de práctica clínica de la Sociedad Española de Cardiología en la angina inestable/infarto sin elevación ST. Rev Esp Cardiol2000; 53: 838-850 (Medline) (Texto completo)
63.  Boden WE. Defining the optimal pharmacotherapy of non-ST-segment elevation (NSTE) acute coronary syndromes (ACS): a rapidly moving target. Curr Opinion Cardiol 2001;16:370-374 (Medline)
64.  Cairns JA, Theroux P, Lewis HD Jr, Ezekowitz M, Meade TW. Antithrombotic agents in coronary artery disease. CHEST 2001; 119: 228S-252S (Medline) (Texto completo)
65.  Yusef S, Flather M, Pogue J, et al. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. Lancet 1998;352:507-14 (Medline) (Texto completo)
66.  Cannon CP. TACTICS-TIMI 18 results. Presented at the American Heart Association Scientific Sessions 2000, New Orleans, LA, November 12-15, 2000
67.  Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomized trial. Lancet 2000;356:9-16 (Medline) (Texto completo)
68.  Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med 1998;338:1785-92 (Medline) (Texto completo)
69.  Stone PH, Thompson B, Zaret BL, et al. Factors associated with failure of medical therapy in patients with unstable angina and non-Q-wave myocardial infarction: a TIMI-IIIB database study. Eur Heart J 1999;20:1084-93 (Medline)
70.  O'Hern M, O'Rourke RA, Wade MJ, et al. A risk stratification model to predict mortality in non-Q-wave myocardial infarction randomized to an early invasive or conservative management strategy [abstr]. Circulation 2000;102(suppl):II-753
71.  Topol EJ, Mark DB, Lincoff AM, et al for the EPISTENT Investigators. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomized trial. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 1999;354;2019-2024 (Medline) (Texto completo)
72.  Heeschen C, Hamm CW, Due A, Langenbrink L, White H. Costs and effectivity of treatment with tirofiban in patients with unstable angina- results from the PRISM trial [abstr]. J Am Coll Cardiol 2000;35(suppl):393ª
73.  Weintraub WS, Thompson TD, Culler S, et al. Targeting patients undergoing angioplasty for thrombus inhibition: a cost-effectiveness and decision support model. Circulation 2000;102:392-8 (Medline) (Texto completo)
74.  Mark DB, Harrington RA, Lincoff AM, et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 2000;101:366-71 (Medline) (Texto completo)
75.  75. The PRICE Investigators. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: prairie ReoPro versus integrilin cost evaluation (PRICE) trial. Am Heart J 2001;141:402-9 (Medline) (Texto completo)
76.  Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533 (Medline) (Texto completo)
77.  Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Circulation 1997; 96(5):1445-1453 (Medline) (Texto completo)
78.  Neumann F-J, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000;35:915-921 (Medline)
79.  Bosch X. Marrugat J. Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST segment elevation myocardial infarction (Cochrane Review). In: The Cochrane Library 4,2001. Oxford. Update software.

 Indice